Product Description
Collagenase clostridium histolyticum injection is used to treat Dupuytren's contracture with a palpable cord. It is also used to treat Peyronie's disease with a palpable plaque and curvature deformity in men. (Sourced from: https://www.mayoclinic.org/drugs-supplements/collagenase-clostridium-histolyticum-injection-route/description/drg-20073911)
Mechanisms of Action: MMP Inhibitor
Novel Mechanism: No
Modality: Nondrug
Route of Administration: Oral,Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Bulgaria | Canada | European Medicines Agency | Greece | Hungary | Ireland | Lithuania | Malaysia | Poland | Portugal | Slovakia | Slovenia | Sweden
Approved Indications: Contracture | Dupuytren Contracture | Cellulite
Known Adverse Events: Pain Unspecified | Contracture | Dupuytren Contracture | Edema | Erythema | Pruritus
Company: Endo
Company Location: DUBLIN 4 L2 00000
Company CEO: Blaise Coleman
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Cellulite|Edema
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| APHRODITE | P2 |
Completed |
Cellulite|Edema |
2023-01-03 |
24% |
| EN3835-224 | P2 |
Completed |
Cellulite|Edema |
2021-08-30 |